Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Flexion Therapeutics (FLXN) yesterday and set a price target of $15.00. The company’s shares closed last Wednesday at $7.53, close to its 52-week low of $6.71.
According to TipRanks.com, Brisebois is a 2-star analyst with an average return of 2.5% and a 34.7% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals, Diamedica Therapeutics, and Kala Pharmaceuticals.
Flexion Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $20.63, which is a 182.2% upside from current levels. In a report issued on April 28, Northland Securities also assigned a Buy rating to the stock with a $35.00 price target.
See today’s analyst top recommended stocks >>
Flexion Therapeutics’ market cap is currently $362.1M and has a P/E ratio of -2.70. The company has a Price to Book ratio of -20.95.
Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FLXN in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand. The company was founded by Michael D. Clayman and Neil Bodick in 2007 and is headquartered in Burlington, MA.
